CheckMate-227 Meets Co-Primary End Point of PFS with Nivolumab/Ipilimumab Combination in NSCLC, Confirms TMB as Viable Biomarker

TON Web Exclusives - Lung Cancer

Top-line results from the ongoing phase 3 CheckMate-227 trial have shown that treatment with the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) led to statistically significant progression-free survival (PFS) benefit (the study’s co-primary end point) compared with chemotherapy in the first-line treatment of patients with advanced non–small-cell lung cancer (NSCLC) and high tumor mutation burden (TMB), regardless of programmed death-ligand 1 (PD-L1) expression. These results highlight the potential of TMB as a biomarker to identify patients who will respond to immune checkpoint inhibitors.

“TMB has emerged as an important biomarker for the activity of immunotherapy. For the first time, this phase 3 study shows superior PFS with first-line combination immunotherapy in a predefined population of NSCLC patients with high TMB,” said Matthew D. Hellmann, MD, a CheckMate-227 investigator and medical oncologist at Memorial Sloan Kettering Cancer Center, New York, NY. “CheckMate-227 showed that TMB is an important, independent predictive biomarker that can identify a population of first-line NSCLC patients who may benefit from the nivolumab plus ipilimumab combination,” he said.

In tumor cells, high TMB corresponds with high levels of neoantigens, peptides that could aid the immune system in recognizing tumors and spur an increase in T-cells and overall antitumor response. In the CheckMate-227 trial, high TMB was defined as ≥10 mutations/megabase, and was measured using FoundationOne CDx, an analytically validated assay from Foundation Medicine. Of patients evaluated for TMB, approximately 45% were classified as having high TMB.

The safety profile of the regimen was consistent with that of previous results in first-line NSCLC for the combination dosing schedule of nivolumab 3 mg/kg every 2 weeks and ipilimumab 1 mg/kg every 6 weeks.

The results come from an analysis of patients from Part 1 of the open-label trial, which consists of Part 1a (which evaluated nivolumab plus ipilimumab and nivolumab monotherapy vs chemotherapy in PD-L1–positive patients with NSCLC) and Part 1b (which evaluated nivolumab plus ipilimumab and nivolumab plus chemotherapy vs chemotherapy in patients whose tumors do not express PD-L1). In addition to PFS, the co-primary end point of the trial is overall survival (OS) in PD-L1–positive patients.

Part 2 of the trial is assessing nivolumab plus chemotherapy versus chemotherapy across a broad population, with OS as the primary end point. The Data Monitoring Committee recommended that the study continue, based on an interim analysis for OS.

Overall, CheckMate-227 has randomized >2500 patients with squamous and nonsquamous advanced NSCLC to evaluate nivolumab-based regimens compared with platinum-doublet chemotherapy as first-line treatments. Results of the study will be presented at a future medical congress.

Source                                               
Pivotal phase 3 CheckMate-227 study demonstrates superior progression-free survival (PFS) with the Opdivo plus Yervoy combination versus chemotherapy in first-line non-small cell lung cancer (NSCLC) patients with high tumor mutation burden (TMB). February 5, 2018. https://news.bms.com/press-release/bms/pivotal-phase-3-checkmate-227-study-demonstrates-superior-progression-free-surviva. Accessed February 22, 2018.

Related Items
NCCN Drug Affordability Ratings Miss the Mark in Lung Cancer
TOP Web Exclusives published on October 9, 2018 in Lung Cancer
A Home Run for Pembrolizumab plus Chemotherapy Combination in Newly Diagnosed Metastatic Non–Small-Cell Lung Cancer
Phoebe Starr
TOP - August 2018, Vol 11, No 2 published on August 3, 2018 in Lung Cancer
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Lung Cancer
Treatment Paradigm Shift in ALK-Positive NSCLC Raises Further Questions Regarding ALK Inhibitor Sequencing
TON Web Exclusives published on March 16, 2018 in Lung Cancer
FDA Grants Orphan Drug Designation to Seribantumab, an Investigational Treatment for Heregulin-Positive NSCLC
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Three Leading Medical Societies Update Molecular Testing Guideline for Lung Cancer TKI Treatment
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Brigatinib May Prolong Survival After Progression of Crizotinib-Refractory, ALK-Positive NSCLC
TON Web Exclusives published on March 16, 2018 in Lung Cancer
Osimertinib Nearly Doubles PFS, Receives Breakthrough Therapy Designation in Frontline Treatment of EGFR-Positive NSCLC
TON Web Exclusives published on February 12, 2018 in Lung Cancer
Pembrolizumab, Pemetrexed, and Platinum Chemotherapy Combination Shows Improved OS and PFS in Patients with Metastatic Nonsquamous NSCLC
TON Web Exclusives published on February 12, 2018 in Lung Cancer
FDA Approves Alectinib for ALK-Positive, Metastatic Non–Small-Cell Lung Cancer
TON Web Exclusives published on February 12, 2018 in Lung Cancer
Last modified: March 16, 2018